Intelligence Platform

Patents

Browse 120 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed

patent

US 11464830

Treatment of inflammatory conditions by delivery of interleukin-1 receptor antagonist fusi

REGENERON PHARMACEUTICALS, INC. · Granted Tue Oct 11 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11421036

Methods of treating eosinophilic esophagitis by administering an antibody which inhibits i

REGENERON PHARMACEUTICALS, INC. · Granted Tue Aug 23 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 18 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11352403

Activatable interleukin-2 polypeptides and methods of use thereof

Werewolf Therapeutics, Inc. · Granted Tue Jun 07 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 02 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11352402

Interleukin-4 receptor-binding fusion proteins and uses thereof

Medicenna Therapeutics Inc. · Granted Tue Jun 07 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 02 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11318164

Immunotherapeutic treatment method using an interleukin-2 receptor beta-selective agonist

Nektar Therapeutics · Granted Tue May 03 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11118186

Soluble interleukin-7 receptor (sIL7R) modulating therapy to treat autoimmune diseases and

The Board of Regents of the University of Texas System · Granted Tue Sep 14 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11098127

Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies

REGENERON PHARMACEUTICALS, INC. · Granted Tue Aug 24 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 19 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11091525

Method of refolding an interleukin-2 (IL-2) protein

Nektar Therapeutics · Granted Tue Aug 17 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 12 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11084856

Interleukin-4 receptor-binding fusion proteins and uses thereof

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Aug 10 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 05 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11059896

Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jul 13 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11041000

Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases

Protagonist Therapeutics, Inc. · Granted Tue Jun 22 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 17 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11026997

Treatment of inflammatory conditions by delivery of interleukin-1 receptor antagonist fusi

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jun 08 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11013787

Sustained release formulation of interleukin-10 for wound treatment and related methods

THE REGENTS OF THE UNIVERSITY OF COLORADO FOR AND ON BEHALF OF THE UNIVERSITY OF COLORADO DENVER · Granted Tue May 25 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 20 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11008314

Compounds and methods for modulating interleukin-2-inducible t-cell kinase

Corvus Pharmaceuticals, Inc. · Granted Tue May 18 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 13 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11007265

Vaccines having an antigen and interleukin-21 as an adjuvant

Inovio Pharmaceuticals, Inc. · Granted Tue May 18 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 13 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10941183

Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bow

Protagonist Therapeutics, Inc. · Granted Tue Mar 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10933130

Vaccines with interleukin-33 as an adjuvant

Inovio Pharmaceuticals, Inc. · Granted Tue Mar 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10851158

Biomarkers related to interleukin-33 (IL-33)-mediated diseases and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Dec 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10787490

Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases

Protagonist Therapeutics, Inc. · Granted Tue Sep 29 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10781242

Interleukin-2 fusion proteins and uses thereof

Medicenna Therapeutics Inc. · Granted Tue Sep 22 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 17 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10738112

Anti-human interleukin-17A monoclonal antibody

SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD. · Granted Tue Aug 11 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 06 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10696724

Activatable interleukin-2 polypeptides

Werewolf Therapeutics, Inc. · Granted Tue Jun 30 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 25 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10611845

Activatable antibodies that bind interleukin-6 receptor and methods of use thereof

CytomX Therapeutics, Inc. · Granted Tue Apr 07 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10435473

Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies

REGENERON PHARMACEUTICALS, INC. · Granted Tue Oct 08 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted